市場調査レポート

分子診断の世界市場

The Global Molecular Diagnostics Market

発行 Medtech Insight 商品コード 333653
出版日 ページ情報 英文 272 Pages, 59 Exhibits, 7 Company Profiles
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=104.18円で換算しております。
Back to Top
分子診断の世界市場 The Global Molecular Diagnostics Market
出版日: 2015年06月29日 ページ情報: 英文 272 Pages, 59 Exhibits, 7 Company Profiles
概要

分子診断製品市場は、世界の体外診断 (IVD) 市場における最も成長率の高いセグメントであり、その規模は2014年に53億米ドルと推計され、今後は6.6%のCAGRで推移し、2019年までに73億米ドルに達すると予測されています。この成長は、予測期間中に4.2%の複利年率で拡大が見込まれる世界のIVD製品市場が比較的穏やかな成長であるにも関わらず、発生しています。

当レポートでは、世界の分子診断市場について調査分析し、各製品市場の主な成長影響因子、主要サプライヤーの市場シェア・売上予測、各製品市場における主要サプライヤーの製品ポートフォリオ分析、新しい分子診断アッセイを開発する新興企業、分子診断市場における新しい機会分野、および製品市場の発展を変化し得る革新的技術などについて、体系的な情報を提供しています。

第1章 市場環境

  • 世界の分子診断市場における動向
  • 分子診断の導入促進因子
  • 分子診断の標的市場セグメント

第2章 分子診断向け標的疾患の疫学

  • 感染症
  • 腫瘍
  • 遺伝病
  • 血液スクリーニング
  • 分子診断アプリケーションを用いるその他の疾患
  • 将来の分子診断アプリケーション

第3章 技術考察

  • ポリメラーゼ連鎖反応 (PCR)
  • 等温核酸増幅技術
  • ハイブリダイゼーション
  • 核酸シーケンシングおよび次世代シーケンシング
  • マイクロアレイ
  • その他の分子診断技術
  • 検査方法・計測技術
  • オートアナライザーとセミオートアナライザーの機能比較

第4章 地域考察

  • 北米
    • ラボ業務
    • 経済的要因
    • 規制要因
    • 人口統計・社会的要因
    • 技術動向
  • 欧州 (フランス・ドイツ・イタリア・スペイン・英国・その他欧州)
  • アジア太平洋
  • その他 (ROW)

第5章 分子診断市場分析・予測

  • 市場成長促進因子・抑制因子
  • エンドユーザー特徴
  • 感染症検査における分子診断市場
  • 腫瘍における分子診断市場
  • 遺伝子検査における分子診断市場
  • 血液スクリーニングにおける分子診断市場
  • その他の分子診断市場

第6章 競合考察

  • 主要サプライヤーの売上・市場シェア
  • 市場浸透戦略
  • 市場参入障壁・リスク
  • ビジネスプランニングの課題・懸念事項

第7章 企業プロファイル

  • AdvanDx
  • Asuragen
  • AutoGenomics
  • Bioneer
  • Chronix Biomedical
  • Illumina
  • SeeGene
  • Xagenic

付録:企業リスト

参考文献

目次
Product Code: A344

The molecular diagnostic products market is the highest growth segment of the global in vitro diagnostics (IVDs) market valued at an estimated $5.3 billion in 2014 and projected to grow at a compound annual growth rate of 6.6% to $7.3 billion by the year 2019. This growth is forecast to occur in spite of relatively modest growth in the overall worldwide market for IVD products, which is estimated to be expanding at a compound annual rate of 4.2% for the same period. To some extent, growth of the molecular diagnostics market will occur at the expense of certain segments of the conventional diagnostic products market, including cell culture testing, immunoassay products for infectious diseases, immunoassays for cancer diagnosis and screening, and conventional products for genetic testing. Individual product segments covered in this report include molecular diagnostics for infectious disease, blood screening, genetic testing, and cancer diagnosis and screening.

This report will cover:

  • worldwide procedure and market forecasts for the years 2014 to 2019;
  • key factors influencing the growth of individual product markets;
  • estimated market shares and sales among leading suppliers;
  • major supplier product portfolio analysis in individual product markets;
  • emerging companies developing novel molecular diagnostic assays;
  • emerging areas of opportunity in the molecular diagnostic market; and,
  • innovative technology that could potentially change the way product markets develop.

Methodology

Reports are produced exclusively by Medtech Insight, through extensive primary and secondary research among the clinicians, researchers, and competitors in the marketplace, and draw upon the industry expertise of a network of industry insiders. Medtech Insight exhaustively corroborates the data as a baseline for completing forward-looking analysis and providing insight into product, technology and market evolution.

Table of Contents

EXECUTIVE SUMMARY

  • i. Methodology
  • Exhibit ES-1: Global Clinical Diagnostics, Combined Market Forecast, 2013-2019

1. MARKET ENVIRONMENT

  • 1.1 Trends in the Worldwide Molecular Diagnostics Market
  • 1.2 Factors Driving Adoption of Molecular Diagnostics
    • 1.2.1 Advantages of Molecular Testing Versus Immunoassay and Biochemical Methods
    • 1.2.2 Companion Diagnostics and Pharmacogenomics
    • 1.2.3 Reimbursement and Funding Issues
    • 1.2.4 Regulatory Issues
    • 1.2.5 Liability Issues
  • 1.3 Target Market Segments for Molecular Diagnostics
    • 1.3.1 Molecular Diagnostics for Infectious Disease Testing
    • 1.3.2 Molecular Diagnostics for Blood Screening
    • 1.3.3 Molecular Diagnostics for Cancer Screening
    • 1.3.4 Genetic Testing Segment
  • Exhibit 1-1: Comparison of Applicability of Molecular, Immunochemical, and Biochemical Assay Technology in Major Disease Categories
  • Exhibit 1-2: Worldwide Adoption of Nucleic Acid Testing Technology for Infectious Agent Screening of Donated Blood and Blood Products

2. EPIDEMIOLOGY OF TARGET DISEASES FOR MOLECULAR DIAGNOSTICS

  • 2.1 Infectious Disease
    • 2.1.1 Hepatitis B Virus
    • 2.1.2 Hepatitis C Virus
    • 2.1.3 Human Immunodeficiency Virus
    • 2.1.4 Tuberculosis
    • 2.1.5 Chlamydia trachomatis/Neisseria gonorrhea
    • 2.1.6 Human Papilloma Virus
    • 2.1.7 Methicillin-resistant Staphylococcus aureus
    • 2.1.8 Other Infectious Diseases
    • 2.1.9 Microbiological Identification and Susceptibility Testing
  • 2.2 Oncology
    • 2.2.1 Prostate Cancer
    • 2.2.2 Breast Cancer
    • 2.2.3 Colorectal Cancer
    • 2.2.4 Other Cancers
  • 2.3 Genetic Disease
  • 2.4 Blood Screening
  • 2.5 Other Diseases with Molecular Diagnostic Applications
  • 2.6 Future Applications of Molecular Diagnostics
    • 2.6.1 Molecular Diagnostics in Alzheimer's Disease
    • 2.6.2 Molecular Diagnostics in Cardiovascular Disease
    • 2.6.3 Molecular Diagnostics in Diabetes and Other Metabolic Disorders
  • Exhibit 2-1: Worldwide Infectious Disease Incidence and Prevalence Estimates
  • Exhibit 2-2: 2012, Estimated Cancer Incidence by Type and Region
  • Exhibit 2-3: 2012, Estimated Cancer Prevalence by Type and Region
  • Exhibit 2-4: Global Trends in Cancer Incidence and Cancer Deaths
  • Exhibit 2-5: 2012, Projected Trends in Worldwide Incidence of the Major Types of Cancer
  • Exhibit 2-6: Tumor-Associated Infectious Agents and Related Cancer Incidence for 2012
  • Exhibit 2-7: Incidence and Risk for Major Types of Genetic Disease
  • Exhibit 2-8: Trends in Blood Collection in the U.S.
  • Exhibit 2-9: Trends in Blood Collection in Europe
  • Exhibit 2-10: Hemostasis Disorders and Prevalence
  • Exhibit 2-11: U.S. Organ Transplant Procedures, 2008-2014
  • Exhibit 2-12: Organ Transplant Procedures and Recipient Waiting Lists in Eurotransplant Countries, 2009-2013
  • Exhibit 2-13: Worldwide Incidence and Prevalence of Cardiovascular Disease by Region
  • Exhibit 2-14: Global Diabetes Prevalence Trends

3. TECHNOLOGY INSIGHTS

  • 3.1 Polymerase Chain Reaction
  • 3.2 Isothermal Nucleic Acid Amplification Technology
  • 3.3 Hybridization
  • 3.4 Nucleic Acid Sequencing and Next-Generation Sequencing
  • 3.5 Microarrays
  • 3.6 Other Molecular Diagnostic Technologies
  • 3.7 Testing Methodologies and Instrumentation Technologies
    • 3.7.1 Instrument Technologies
    • 3.7.2 Reagent Technologies
    • 3.7.3 Software and Service
  • 3.8 Feature Comparison of Automated and Semi-Automated Analyzers
  • Exhibit 3-1: Characteristics of Nucleic Acid Amplification Technologies
  • Exhibit 3-2: Next-Generation Sequencing Technologies
  • Exhibit 3-3: Microarray Technologies for Molecular Diagnostics
  • Exhibit 3-4: Labeling Technologies for Molecular Diagnostics
  • Exhibit 3-5: Feature Comparison of Molecular Diagnostic Assay Systems

4. REGIONAL INSIGHTS

  • 4.1 North America
    • 4.1.1 Laboratory Practices
    • 4.1.2 Economic Factors
    • 4.1.3 Regulatory Factors
    • 4.1.4 Demographic and Social Factors
    • 4.1.5 Technological Trends
  • 4.2 Europe (France, Germany, Italy, Spain, the United Kingdom, Rest of Europe)
    • 4.2.1 Laboratory Practices
    • 4.2.2 Economic Factors
    • 4.2.3 Regulatory Factors
    • 4.2.4 Demographic and Social Factors
    • 4.2.5 Technological Trends
  • 4.3 Asia Pacific
    • 4.3.1 Laboratory Practices
    • 4.3.2 Economic Factors
    • 4.3.3 Regulatory Factors
    • 4.3.4 Demographic and Social Factors
    • 4.3.5 Technological Trends
  • 4.4 Rest of the World
    • 4.4.1 Laboratory Practices
    • 4.4.2 Economic Factors
    • 4.4.2 Regulatory Factors
    • 4.4.4 Demographic and Social Factors
    • 4.4.5 Technological Trends
  • Exhibit 4-1: 2015, Molecular Diagnostic Products Market by Region
  • Exhibit 4-2: Number of Clinical Laboratories in Selected Countries
  • Exhibit 4-3: Time and Cost for Market Clearance or Approval for In Vitro Diagnostic Products
  • Exhibit 4-4: United States Population Trend Data, 2014-2020
  • Exhibit 4-5: Percentage of Molecular Diagnostic Patents and Patent Applications by Applicant Region
  • Exhibit 4-6: Population Trends in Europe, 2015-2020
  • Exhibit 4-7: Total healthcare Expenditure as a Percentage of Gross Domestic Product in Major Countries in Asia Versus the United States and Europe
  • Exhibit 4-8: Population Trends in the Asia-Pacific Region, 2015-2020
  • Exhibit 4-9: Total healthcare Expenditure as a Percentage of Gross Domestic Product in Major Countries in Asia Versus the United States and Europe
  • Exhibit 4-10: Population Trends in Latin America and Africa, 2015-2020

5. MOLECULAR DIAGNOSTICS MARKET ANALYSIS AND FORECASTS

  • 5.1 Market Drivers and Limiters
  • 5.2 End User Characteristics
  • 5.3 Markets for Molecular Diagnostics in Infectious Disease Testing
    • 5.3.1 Existing Molecular Diagnostics Infectious Disease Testing Applications
    • 5.3.2 Applications in Development in Infectious Disease Testing
    • 5.3.3 Molecular Diagnostic Infectious Disease Testing Products and Products in Development
    • 5.3.4 Infectious Disease Molecular Diagnostics Market Forecast by Region
    • 5.3.5 Competitive Analysis
  • 5.4 Markets for Molecular Diagnostics in Oncology
    • 5.4.1 Existing Molecular Diagnostics for Oncology Testing Applications
    • 5.4.2 Applications in Development in Oncology
    • 5.4.3 Molecular Diagnostic Products for Oncology Testing Currently Available or in Development
    • 5.4.4 Molecular Diagnostics Oncology Market Forecast by Region
    • 5.4.5 Competitive Analysis
  • 5.5 Markets for Molecular Diagnostics in Genetic Testing
    • 5.5.1 Existing Molecular Genetic Diagnostic Applications
    • 5.5.2 Genetic Testing Applications in Development
    • 5.5.3 Molecular Genetic Diagnostic Products Currently Available and in Development
    • 5.5.4 Molecular Genetic Diagnostic Products Market Forecast by Region
    • 5.5.5 Competitive Analysis
  • 5.6 Markets for Molecular Diangostics in Blood Screening
    • 5.6.1 Existing Molecular Blood Screening Applications
    • 5.6.2 Applications in Development for Molecular Blood Screening
    • 5.6.3 Molecular Blood Screening Products Currently Available and in Development
    • 5.6.4 Molecular Blood Screening Markets by Region
    • 5.6.5 Competitive Analysis
  • 5.7 Other Markets for Molecular Diagnostics
    • 5.7.1 Emerging Molecular Diagnostics Markets for Neurological Disorders
    • 5.7.2 Emerging Molecular Diagnostic Markets in Cardiovascular Disease
    • 5.7.3 Emerging Molecular Diagnostic Markets in Diabetes and Metabolic Disease
  • Exhibit 5-1: Trends in Reported Chlamydia and Gonorrhea Cases
  • Exhibit 5-2: Number of Target Patients Worldwide for Select Molecular Diagnostic Tests
  • Exhibit 5-3: Infectious Disease Molecular Diagnostic Products on the Market or in Development
  • Exhibit 5-4: Worldwide Markets for Infectious Disease Diagnosis and Viral Load Monitoring Products, 2013-2019
  • Exhibit 5-5: Worldwide Market for Molecular Infectious Disease Diagnosis and Viral Load Monitoring Products by Region, 2013-2019
  • Exhibit 5-6: Supplier Sales and Market Shares for Molecular Infectious Disease Diagnosis and Viral load Monitoring Products by Region
  • Exhibit 5-7: Trends in Global Cancer Incidence, 2012-2035
  • Exhibit 5-8: Select Oncogenes and Tumor Suppressor Genes and Associated Clinical Applications
  • Exhibit 5-9: New Cancer Cases Attributable to Infectious Diseases Worldwide
  • Exhibit 5-10: Molecular Cancer Diagnostic Products on the Market or in Development
  • Exhibit 5-11: Worldwide Market for Molecular Cancer Testing Products by Region, 2013-2019
  • Exhibit 5-12: Worldwide Supplier Sales and Market Shares for Molecular Cancer Testing Products by Region, 2014
  • Exhibit 5-13: Worldwide Infectious Disease Incidence and Prevalence Estimates
  • Exhibit 5-14: Pharmacogenomic and Companion Diagnostic Test Applications
  • Exhibit 5-15: Molecular Diagnostic Products for Genetic Testing Applications
  • Exhibit 5-16: Worldwide Market for Molecular Genetic Testing Products by Region, 2013-2019
  • Exhibit 5-17: Worldwide Sales and Market Shares of the Leading Suppliers of Molecular Genetic Testing Products
  • Exhibit 5-18: Molecular Blood Screening Products
  • Exhibit 5-19: Worldwide Market for Molecular Blood Screening Products by Region, 2013-2019
  • Exhibit 5-20: Sales and Market Shares for the Leading Suppliers of Molecular Blood Screening Products by Region
  • Exhibit 5-21: Major Neurological Diseases Representing Potential Applications for Molecular Diagnostics
  • Exhibit 5-22: Major Cardiovascular Disorders Representing Potential Applications for Molecular Diagnostics
  • Exhibit 5-23:..... Major Genes Associated with an Increased Risk of Diabetes

6. COMPETITOR INSIGHTS

  • 6.1 Sales and Market Shares of Leading Suppliers
  • 6.2 Market Penetration Strategies
  • 6.3 Market Entry Barriers and Risks
  • 6.4 Business Planning Issues and Concerns
  • Exhibit 6-1: Selected Competitors in the Global Molecular Diagnostics Market
  • Exhibit 6-2: Market Segment Participation of Leading Competitors in the Molecular Diagnostics Market
  • Exhibit 6-3: 2014, Worldwide Molecular Diagnostic Product Sales by Region and Global Market Shares for Leading Suppliers
  • Exhibit 6-4: Major Business Transactions in the Molecular Diagnostics Industry

7. COMPANY PROFILES

  • 7.1 AdvanDx
  • 7.2 Asuragen
  • 7.3 AutoGenomics
  • 7.4 Bioneer
  • 7.5 Chronix Biomedical
  • 7.6 Illumina
  • 7.7 SeeGene
  • 7.8 Xagenic

APPENDIX: COMPANY LISTING

BIBLIOGRAPHY

Back to Top